Evaluation of Nucleic Acid Stabilization Products for Ambient Temperature Shipping and Storage of Viral RNA and Antibody in a Dried Whole Blood Format

Allison L. Dauner, Theron C. Gilliland Jr., Indrani Mitra, Subhamoy Pal,* Amy C. Morrison, Robert D. Hontz, and Shuenn-Jue L. Wu
Naval Medical Research Center, Silver Spring, Maryland; U.S. Naval Medical Research Unit No. 6 (NAMRU-6), Lima, Peru; Department of Entomology and Nematology, University of California, Davis, California

Abstract. Loss of sample integrity during specimen transport can lead to false-negative diagnostic results. In an effort to improve upon the status quo, we used dengue as a model RNA virus to evaluate the stabilization of RNA and antibodies in three commercially available sample stabilization products: Whatman FTA Micro Cards (GE Healthcare Life Sciences, Pittsburgh, PA), DNASTable Blood tubes (Biomatrica, San Diego, CA), and ViveST tubes (ViveBio, Alpharetta, GA). Both contrived and clinical dengue-positive specimens were stored on these products at ambient temperature or 37°C for up to 1 month. Antibody and viral RNA levels were measured by enzyme-linked immunosorbent assay (ELISA) and quantitative reverse transcription polymerase chain reaction (qRT-PCR) assays, respectively, and compared with frozen unloaded controls. We observed reduced RNA and antibody levels between stabilized contrived samples and frozen controls at our earliest time point, and this was particularly pronounced for the FTA cards. However, despite some time and temperature dependent loss, a 94.6–97.3% agreement was observed between stabilized clinical specimens and their frozen controls for all products. Additional considerations such as cost, sample volume, matrix, and ease of use should inform any decision to incorporate sample stabilization products into a diagnostic testing workflow. We conclude that DNASTable Blood and ViveST tubes are useful alternatives to traditional filter paper for ambient temperature shipment of clinical specimens for downstream molecular and serological testing.

INTRODUCTION

Accurate diagnosis of infectious diseases is needed to inform timely treatment and often requires temperature-controlled transportation of clinical specimens from the primary clinic to a diagnostic laboratory, conditions that may be unavailable in resource-limited environments. Failure to stabilize the specimen during transport could lead to false-negative diagnostic results, particularly for assays requiring viral RNA detection, in part due to the ubiquity of ribonucleases. Recent studies have demonstrated variability in current shipping conditions both in terms of expediency and temperature exposure of the sample. From these studies, one may conclude that sample stabilization prior to transport may be crucial to ensure accuracy of downstream diagnostic testing. To facilitate sample collection and storage in austere environments, such as those experienced during outbreaks of tropical diseases, a stabilization product ideally needs to be inexpensive as well as easy to use, requiring minimal ancillary equipment. In addition, the disease biomarkers in the specimen need to be preserved through the time and conditions to which they will be exposed during transport. Finally, the stabilization method needs to be compatible with all tests likely to be necessary for diagnosis, including molecular assays and serology.

In this study, we used dengue virus (DENV) as a model RNA virus for testing clinical specimen stabilization products for their ability to preserve nucleic acid and antibody in a dried blood format. Dengue is the most prevalent arthropod-borne viral disease, with four antigenically distinct serotypes: DENV1–4. Accurate diagnosis of dengue fever often requires both serological and molecular detection methods to distinguish it from other co-circulating fever-causing infectious agents, making DENV a good candidate for this evaluation. One of the most cost-effective and widely used methods of stabilizing whole blood for future testing is to create a dried blood spot on filter paper such as the Whatman FTA Micro Card (GE Healthcare Life Sciences, Pittsburgh, PA). FTA Micro Cards contain proprietary chemicals that protect nucleic acids from nucleases, as well as ultraviolet and oxidative damage. Many groups have examined the utility of dried blood spots on various types of filter paper for antigen, antibody, and nucleic acid–based diagnostics, especially for viruses of public concern such as the human immunodeficiency virus (HIV). This method is generally considered effective for stabilizing DNA for downstream molecular diagnostic applications. Despite their long-standing and widespread usage, diagnostic accuracy from dried blood spots can be influenced by many factors including original antibody or nucleic acid amount, hematocrit, size of the blood spot, and elution protocol used. Several products have recently entered the market, which may address these shortcomings. Using a proprietary technique based on anhydrosis involving a thermostable dissolvable glass, Biomatrica tubes (Biomatrica, San Diego, CA) “shrink-wrap” DNA in whole blood or purified RNA for long-term ambient temperature storage. Biomatrica DNASTable has been shown to be effective for stabilizing DNA, but no previous studies have evaluated its ability to stabilize RNA in whole blood. Another manufacturer, ViveBio (Alpharetta, GA), has developed ViveST tubes that are claimed to stabilize RNA in dried plasma in a synthetic matrix, thus eliminating the need for upfront extraction. Studies using ViveST tubes have demonstrated hepatitis B, hepatitis C, and HIV nucleic acid stability ranging from 10 to 56 days following storage at ambient temperature. We evaluated these three commercially available specimen stabilization products for their ability to stabilize dengue viral RNA and anti-dengue immunoglobulin. We first tested these products over a period of 4 weeks at ambient and 37°C
temperatures using contrived positive specimens created by spiking whole blood with DENV as well as human anti-dengue IgG. The products were then evaluated using clinical specimens collected and shipped from a dengue-endemic region of South America. RNA and antibody levels were tested using real-time reverse-transcription polymerase chain reaction (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA), respectively, to evaluate the effect of time, storage temperature, and stabilization method on sample integrity. Together, this study represents a comprehensive laboratory and field evaluation of currently available sample stabilization matrices that may represent viable alternatives to dried blood spots.

**MATERIALS AND METHODS**

**Human use statement.** The procedures applied in this study were performed in accordance with the ethical standards of the Naval Medical Research Center (NMRC) Institutional Review Board (IRB) and with the Helsinki Declaration of 1975, as revised in 1983. Serum from dengue-positive patients was collected from febrile patients, who had provided permission for the future use of their blood samples, presenting to 12 health facilities within or near Iquitos, Peru, as part of an ongoing febrile surveillance study. Study protocols were approved by NMRC and the U.S. Naval Medical Research Unit No. 6 (NAMRU-6) IRB in compliance with all applicable federal regulations governing the protection of human subjects. (NMRC.2005.0007 and NAMRU6.2014.0015).

**Sample preparation and stabilization.** Contrived DENV-positive samples. DENV-positive samples were modeled by spiking commercially available CPDA-1-treated whole blood (Valley Biomedical, Winchester, VA) with tissue culture–derived DENV1 (West Pac-74) to a final titer of 10^4 plaque-forming units (PFU)/mL and anti-dengue IgG-positive human plasma pooled from de-identified donors. Clinical DENV-positive specimens. Whole venous blood was collected into purple-top ethylenediaminetetraacetic acid (EDTA) tubes during ongoing surveillance studies from febrile individuals reporting to 12 health facilities in Iquitos. Samples were collected between 07:30 AM and 1:00 PM and stored at 4°C until they were transported on ice to the NAMRU-6 field laboratory for processing by 2:00 PM. Thirty-seven specimens were confirmed to be dengue positive by the SD BIOLINE Dengue Duo (Dengue NS1 Ag and IgG/IgM) immunochromatographic rapid test (Alere Inc., Waltham, MA); dengue infection was later confirmed by RT-PCR and qRT-PCR as described elsewhere.

**Sample elution and extraction.** Elution. The DNASTABLE Blood tubes were reconstituted according to manufacturer’s recommendations. In brief, 300 μL of molecular grade water was added to each DNASTABLE Blood tube at the appropriate time point, and the tube agitated at 1,000–1,200 rpm for 1 hour at ambient temperature. The ViveST tubes were also eluted according to manufacturer’s recommendation: the matrix was placed into a sealed standard, commercially available 3-mL syringe, after which 1 mL of water was added to the matrix and the syringe gently shaken to distribute the water. After 10 minutes, the plunger was used to expel all volume into a 1.5-mL microcentrifuge tube. Nucleic acid was then eluted by adding 300 μL AVL buffer (catalog no. 19073; QIAgen, Valencia CA) to each tube and shaking for 1 hour at ambient temperature 1,000–1,200 rpm, while antibodies were eluted by adding 300 μL of 0.1% PBS-Tween20 (Corning CellGro, Manassas, VA; Fischer Scientific, Fair Lawn, NJ) to each tube and holding them overnight at 4°C. All eluates were then frozen at ~80°C until the end of the study.

**RNA extraction.** Using either a QIAgen EZ1 Advanced XL automated extractor (contrived samples) or QIAgen QIAamp viral RNA Mini kits (clinical specimens), 140 μL eluate was extracted according to the manufacturer’s protocols. Samples extracted using the QIAgen EZ1 Advanced XL were first diluted to 400 μL with 260 μL ATL buffer (catalog no. 19076; QIAgen) as required by the EZ1 Virus Mini Kit v.2.0 (catalog no. 955134). RNA was eluted in a final volume of 60 μL for downstream molecular characterization using qRT-PCR.

**Copy number and antibody concentration determination.** The presence of DENV RNA was determined using a qRT-PCR protocol as previously described. All specimens were run using the Applied Biosystems 7500 Fast Dx Real-Time PCR system (Life Technologies, Carlsbad, CA). The TaqMan EZ RT-PCR Core Reagent Kit (catalog no. N8080236; Life Technologies) was used with primers and a FAM-BHQ-labeled probe from Integrated DNA Technologies (Coralville, IA). Viral copy number was determined by utilizing a quantitated standard curve of dengue armored RNA (catalog no. 42044; Asuragen, Austin, TX). Anti-dengue IgM and IgG antibodies were analyzed using the Dengue Virus IgM Capture DxSelect and Dengue Virus IgG DxSelect ELISA kits, respectively (catalog no. EL1500M and EL1500G; Focus Diagnostics, Cypress, CA). All optical densities (ODs) were read at 450 nm within 30 minutes of adding stop solution.
**RESULTS**

**Recovery of nucleic acids from stabilization products.** Three nucleic acid stabilization products were evaluated extensively (Table 1). Contrived samples were added to the products according to the manufacturer’s instructions, dried overnight, and then eluted as described in the section Materials and Methods. The contrived samples were also maintained at −80°C without application of any stabilization product, as a frozen unloaded positive control for each experiment. We first tested the amount of dengue RNA for day 0, immediately following the overnight drying step. DENV RNA copies were then measured using qRT-PCR and compared against their corresponding frozen unloaded positive control. Any changes observed at this time point are likely based on application and recovery of sample from the stabilization matrix. We found that application and elution from both DNAStable Blood tubes and FTA Micro Cards lead to a decrease in detectable DENV RNA, from 5.17 ± 0.51 to 4.63 ± 0.66 (Mann–Whitney test, \(P = 0.046\)) and 5.17 ± 0.60 to 3.36 ± 0.15 (\(P = 0.012\)) log_{10} copies/mL, respectively (Table 2). The decrease in RNA recovered from ViveST tubes was not statistically significant, with 5.24 ± 0.57 log_{10} copies/mL in frozen unloaded whole blood compared with 4.92 ± 0.51 log_{10} copies/mL at day 0 (\(P = 0.103\)).

**Stabilization of nucleic acids and antibodies over time.** We next wanted to examine the effect of time and temperature on RNA stability when using stabilization products. Using contrived dengue-positive samples, we found that DNAStable Blood and ViveST tubes were able to stabilize RNA at ambient temperature for at least 28 days with no significant loss in copy number when compared with day 0 (Table 2). RNA stabilized on DNAStable Blood tubes was determined to be 4.63 ± 0.66 (day 0) versus 4.33 ± 0.68 (day 28) log_{10} copies/mL, while RNA stabilized on ViveST tubes was 4.92 ± 0.51 (day 0) versus 4.57 ± 0.58 (day 28) log_{10} copies/mL. There was a significant difference in DENV copy number from day 0 to day 28 when stabilized at ambient temperature using FTA Micro Cards (3.36 ± 0.15 versus 2.80 ± 0.12 log_{10} copies/mL, \(P = 0.005\)). When temperature was elevated to 37°C, all products demonstrated significant decreases in RNA recovery following 28 days of exposure (\(P < 0.05\)). The copy number declined from 4.63 ± 0.66 to 3.8 ± 0.67 log_{10} copies/mL for DNAStable Blood tubes, 4.92 ± 0.51 to 3.79 ± 0.85 log_{10} copies/mL for ViveST tubes, and 3.36 ± 0.15 to 2.60 ± 0.23 log_{10} copies/mL on FTA Micro Cards (Table 2).

IgG titers for the same contrived dengue-positive samples that were dried in the blood tubes, were also stored for up to 28 days at ambient temperature or 37°C, and measured using a commercial ELISA at various time points. As with nucleic acid, a difference was observed between the index value of frozen unloaded positive controls and contrived samples stabilized on DNAStable Blood or ViveST tubes at day 0 (1.32 ± 0.19 versus 0.74 ± 0.07 or 0.83 ± 0.12, respectively; \(P < 0.05\)). Antibody levels remain stable for at least 28 days on both products at ambient temperature when compared with day 0 (Figure 1), whereas samples held at 37°C for 28 days were significantly different than those held at ambient temperature for the same period (\(P < 0.05\)).

**Shipment of clinical samples from field site to reference laboratory.** We next evaluated the products under real-world shipping conditions using clinical samples. EDTA-treated

---

**Table 1**

| Product          | DNAStable Blood tubes | ViveST tubes | FTA micro cards |
|------------------|-----------------------|--------------|-----------------|
| Company          | Biométrica            | ViveBio      | Whatman         |
| Volume held      | 200 μL                | 1.5 mL       | 200 μL          |
| Sample Recovery  |                       |              |                 |
|                  | • Add 300 μL sterile H2O | • Place matrix in syringe | • Mince ¼ spot |
|                  | • Shake at 1,200 rpm at RT, 1 hour | • Add 1 mL sterile H2O | • Shake at 1,200 rpm at RT, 1 hour |
| Mechanism        | Will stabilize DNA in whole blood in dry form using anhydrobiosis | Will stabilize plasma proteins and nucleic acids in dry form in synthetic matrix | Will stabilize proteins and nucleic acids in whole blood on chemically treated paper |
| Price            | $4.50/tube            | $5.00/tube   | $2.93/card      |

RT = room temperature.

**Table 2**

|               | Day 0         | Day 1         | Day 2         | Day 7         | Day 14        | Day 28        |
|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| DNAStable Blood RT | 4.63 ± 0.66 (−0.54) | 4.59 ± 0.71 (−0.58) | 4.62 ± 0.59 (−0.55) | 4.48 ± 0.51 (−0.69) | 4.43 ± 0.43 (−0.73) | 4.33 ± 0.68 (−0.84) |
| DNAStable Blood 37°C | –             | 4.14 ± 0.61 (−1.02) | 3.98 ± 0.44 (−1.19) | 3.64 ± 0.51 (−1.53) | 3.76 ± 0.45 (−1.41) | 3.8 ± 0.67 (−1.37) |
| ViveST RT       | 4.92 ± 0.51 (−0.32) | 4.65 ± 0.53 (−0.59) | 4.44 ± 0.57 (−0.80) | 4.24 ± 0.54 (−1.01) | 4.24 ± 0.73 (−1.00) | 4.57 ± 0.58 (−0.67) |
| ViveST 37°C     | –             | 4.54 ± 0.53 (−0.71) | 4.57 ± 0.55 (−0.67) | 4.4 ± 0.59 (−0.85) | 4.19 ± 0.67 (−1.05) | 3.79 ± 0.85 (−1.45) |
| FTA Micro Card RT | 3.36 ± 0.15 (−1.81) | 3.24 ± 0.12 (−1.93) | 3.26 ± 0.26 (−1.91) | 3.1 ± 0.08 (−2.07) | 2.93 ± 0.16 (−2.24) | 2.8 ± 0.12 (−2.37) |
| FTA Micro Card 37°C | –             | 3.22 ± 0.18 (−1.95) | 3.12 ± 0.16 (−2.05) | 2.87 ± 0.50 (−2.30) | 2.93 ± 0.17 (−2.24) | 2.6 ± 0.23 (−2.57) |

RT = room temperature.
venous whole blood was collected from individuals with clinical suspicion of dengue and was then tested using the SD BIOLINE Dengue Duo rapid test. Whole blood from acute specimens testing positive for dengue nonstructural protein NS1 was then applied to the sample stabilization products and dried overnight as previously described. The specimens remained in the field laboratory for 0–7 days until they were sent in two shipments at ambient temperature to a centralized laboratory in Lima, where they remained for up to eight additional days prior to elution. During transport, the two shipments were exposed to temperatures ranging from 68.2 to 93.7°F (20.1–34.3°C), and relative humidity from 61.4% to 92.6% (Supplemental Figure 1). A total of 37 specimens were collected for this study, of which 36 were of the DENV2 serotype and 1 specimen remained uncharacterized for serotype due to low copy number.

We first investigated the level of DENV RNA in specimens stored and transported at ambient temperature versus their frozen unloaded matched control by using qRT-PCR. There was a good correlation between stabilized specimens and frozen unloaded matched controls, with correlation coefficients of \( r = 0.796, 0.752, \) and \( 0.877 \) for specimens stabilized on DNAstabile Blood tubes, ViveST tubes, and FTA Micro Cards, respectively (Figure 2). We found a significant difference in the average copy number between frozen unloaded matched controls and stabilized specimens, detecting \( 6.92 \pm 1.4 \log_{10} \text{copies/mL} \) from frozen unloaded matched controls compared with \( 6.26 \pm 1.1, 6.26 \pm 1.2, \) and \( 3.93 \pm 1.0 \log_{10} \text{copies/mL} \) for DNAstabile Blood tubes, ViveST tubes, and FTA Micro Cards, respectively (\( P < 0.01 \) (Figure 2B)). Despite the observed decrease in \( \log_{10} \text{copies/mL} \), \( 36/37 \) (DNAstabile Blood tubes and FTA Micro Cards) or \( 35/37 \) (ViveST tubes) specimens were still qRT-PCR positive, leading to a percent agreement of 94.6–97.3%. Using Bland–Altman analysis (Figure 3), we were able to calculate the mean difference between specimens stored at ambient temperature and their frozen unloaded matched controls. Specimens stabilized on DNAstabile Blood and ViveST tubes demonstrated a similar reduction in \( \log_{10} \text{copy number} \) (0.80 and 0.77, respectively), while specimens eluted from FTA Micro Cards demonstrated significantly lower \( \log_{10} \text{copies/mL} \) than the other two products (3.05, \( P < 0.01 \) using Mann–Whitney).

Next, we looked for the presence of anti-dengue IgM and IgG antibodies after stabilization and shipment, and compared the antibody levels to those in the frozen unloaded
matched controls. As with nucleic acids, there was a strong correlation between clinical specimens shipped on each product and its frozen unloaded matched control (Figure 4A). The Pearson’s correlation coefficients for IgM ELISA index values were 0.983, 0.979, and 0.962 for DNAstāble Blood tubes, ViveST tubes, and FTA Micro Cards, respectively. The levels of anti-dengue IgG were similarly correlated, wherein $r = 0.984$, 0.966, and 0.925, respectively. As a percent of frozen unloaded matched control, IgM recovered from FTA Micro Cards appeared lower than the other two products (73.3% versus 101% and 95.1% for DNAstāble Blood and ViveST tubes, respectively), with high variability (Figure 4B). Interestingly, the average percent recovery of IgG was lower than that seen for IgM, with DNAstāble Blood tubes demonstrating only 84.9% of frozen unloaded matched control followed by ViveBio (62.4%) and FTA Micro Cards (50.4%) (Figure 4B).

**DISCUSSION**

There are several scenarios that require preservation and transportation of biological samples, including research, diagnostic testing, or archival purposes. During infectious disease outbreaks, shipping samples for diagnostic testing becomes particularly urgent, as disease identification may be required to facilitate appropriate patient care and establish public health measures to curtail epidemic spread. In transporting samples from austere field environments to reference laboratories, dry ice or cold-chain shipment may not be available or may be prohibitively expensive. Further, using multiple sample stabilization methods may not be convenient, and one universal method is needed that is cheap, easy to use, and effective for stabilizing samples. To address these requirements, we began by evaluating the ability of three products, DNAstāble Blood tubes, ViveST tubes, and FTA Micro Cards, to stabilize RNA and antibodies over time, both at ambient and tropical temperatures using contrived samples. We then performed an evaluation using clinical specimens under real-world shipping conditions. Some of the products investigated were not intended to stabilize antibodies, or were specifically made to stabilize a specific nucleic acid (e.g., DNAstāble was not intended to stabilize RNA). However, we wanted to test these solutions for all targets, and also expose them to temperatures that they are likely to experience during shipment. Together, this represents a comprehensive evaluation using standardized panels of reagents and real-world shipping conditions, of sample stabilization solutions commercially available today that can still enable diagnostic testing for all relevant biological markers. DNA stabilization on these devices has been reported before, so we focused on measuring RNA and antibody levels. We were able to detect dengue virus RNA as well as anti-dengue antibodies from all products for at least 28 days, even when the products were held at 37°C. Some degradation of RNA was observed, especially when the samples were stored at higher temperatures. We conclude that all three products meet the target profile described earlier, and would be appropriate for short-term ambient temperature shipping from field clinics to diagnostic laboratories.

In addition to the products evaluated in this study, there are also commercially available RNA-stabilizing blood collection tubes such as RNAgard Blood tubes (Biomātrica), PAXgene Blood RNA (BD Biosciences, Oxford, UK), and...
Tempus Blood RNA tubes (Life Technologies). An advantage of this type of product is that the specimen can be collected directly into the stabilization tube, minimizing specimen handling and immediately stabilizing the nucleic acid. These products contain additives purported to stabilize RNA from degradation for 3–11 days at ambient temperature. Previous work in our laboratory confirmed their ability to stabilize RNA (data not shown), but since multiple stabilization techniques per sample is neither convenient nor cost-effective, we further examined these products for their ability to stabilize antibodies. These preliminary studies demonstrated an incompatibility of these tubes with downstream serological testing (i.e., universal false-positive anti-dengue IgG ELISA results). It is therefore important that the suitability of the specimen stabilization method with regard to the desired diagnostic testing be established prior to implementation.

Insufficient elution of clinical specimens from stabilization products can lead to a loss of diagnostic targets unrelated to time- or temperature-dependent degradation. Elution methods reported in the literature or recommended by manufacturer’s can also vary, especially for the Whatman FTA cards. Some methods may be better for eluting certain diagnostic targets than others. The loss can be partly ascribed to the volume of sample applied and eluted from the stabilization product. However, we found that this did not explain the extent of the loss in target that was observed. For example, 200 μL whole blood is dried into DNAstable Blood tubes, followed by reconstitution in 300 μL, which can be represented as a dilution factor of 66% of the original concentration. Similarly, for ViveST tubes, where either 500 μL (clinical specimens) or 1,000 μL (contrived samples) were applied, followed by elution in 1,000 μL, the factor is 50% (clinical specimens) or 100% (contrived samples). Finally, only 50 μL (one-fourth of a 200 μL blot) of the FTA Micro Card is eluted into 300 μL, resulting in a factor of 17%. However, we observed an overall recovery rate of RNA on day 0 of 39% (DNAstable Blood tubes), 49.8% (ViveST tubes), or 1.1% (FTA Micro Cards) of the frozen unloaded control. We hypothesize that adhesion may occur between the target (e.g., nucleic acid and/or antibodies) and the stabilization product reducing recovery, and that this may be particularly pronounced for the FTA Micro Cards. Reduced recovery may lead to inaccurate diagnostic results for specimens stabilized on FTA Micro Cards, particularly those containing lower viral titers. Our group has previously observed that low-titer DENV (10^2 PFU/mL) stabilized on FTA Micro Cards was detectable by qRT-PCR for up to 1 month only about 50% of the time, and other groups have reported similar observations. Despite this loss, all products demonstrated a high-percent agreement using clinical samples in South America. This experiment was designed to capture a real-world shipping and testing scenario using patient samples, and a high agreement might suggest that the loss does not affect the detectability of most clinically relevant titers of dengue virus or antibody. In our study, shipments from Iquitos to Peru were received within 1 day, and it is likely that in other situations the samples may take longer to reach their destination. In future studies, it will be important to interrogate these
products under more challenging conditions, including pro-
longed heat and humidity exposure.

Despite the observed reduction in RNA recovery, FTA
Micro Cards remain one of the most cost-effective and versa-
tile solutions for transporting whole blood samples. Unlike
the other products, a finger stick can directly be applied to
the FTA Micro Card to create a dried blood spot. The
DNAstable Blood and ViveST tubes, on the other hand, are
likely to require trained phlebotomists to perform a venous
blood draw. Advantages of DNAstable Blood tubes include
the simplicity of dried blood reconstitution and the self-
contained nature of the tube, which is an important safety
consideration during the transport of infectious agents.
ViveST tubes are also self-contained, and benefit from being
able to accommodate a larger volume of specimen (up to
1.5 mL). However, the elution procedure for ViveST tubes
does require ancillary supplies (such as a syringe), potentially
adding to the cost per specimen. All products recommend
drying following sample application, which can take several
hours and may delay specimen transportation and ultimately
diagnostic results. One arena that would benefit greatly from
incorporating simple and cost-effective sample stabilization is
disease surveillance. In such studies, a large number of speci-
mens are often collected weekly or monthly in austere envi-
ronments with no access to subzero freezers, which can cost
in excess of $10,000 each, exclusive of energy requirements
that are an additional ~$1,000/year.15 The suitability of each
product for each specific application must be determined sepa-
ately. Our data demonstrate that both ViveST and DNAstable
Blood tubes represent viable alternatives to dried blood spots,
with unique advantages for storing human clinical specimens
for downstream diagnostic testing such as qRT-PCR or ELISA.

Received February 6, 2015. Accepted for publication March 24, 2015.
Published online May 4, 2015.

Note: Supplemental figure appears at www.ajtmh.org.

Acknowledgments: We thank Carolina Guevara and Roger Castillo at
NAMRU-6 for providing clinical samples and reference data for this
study. We also thank Timothy Murray and Brad Nelson for providing
ViveST tubes for evaluation and Anita McClenor (bioMONTR® Labs)
for providing technical support under LP-CRADA-NMR-13-9090.

Financial support: This work was funded by the Military Infectious
Diseases Research Program, L0284_13_NM. The work was supported
by Work Unit Number 6000.RAD1.L.A1332.

Copyright statement: Allison L. Dauner, Theron C. Gilliland Jr.,
Indrani Mitra, Subhamoy Pal, and Shuenn-Jue L. Wu, Naval Medical
Research Center, VRDD/IDD, Silver Spring, MD, E-mails: allison
d.auner@sanofiastpeak.com, theron.c.gilliland.ctr@mail.mil, indrani
.m6@gmail.com, subhamoy.pal.ctr@mail.mil, and shuenn-jue.l.wu.civ@
mail.mil. Amy C. Morrison, UC Davis Department of Entomology and
Nematology, Davis, CA, and NAMRU-6, Clinical Naval, Iquitos, Peru,
E-mail: amy.aegypt@gmail.com. Robert D. Hontz, Department of
Virology, NAMRU-6, Lima, Peru, E-mail: robert.hontz@med.navy.mil.

This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the
original author and source are credited.

REFERENCES

1. Thorp HH, 2000. The importance of being r: greater oxidative sta-

bility of RNA compared with DNA. Chem Biol 7: R33–R36.

2. CLSI, 2010. Quantitative Molecular Methods for Infectious Diseases:
Approved Guideline—Second Edition. MM06-A2. Wayne, PA:
Clinical and Laboratory Standards Institute.

3. Olson WC, Smolkin ME, Farris EM, Fink RJ, Czarkowski AR, Fink
JH, Chianese-Bullock KA, Slingluff CL Jr, 2011. Shipping
blood to a central laboratory in multicenter clinical trials:
effect of ambient temperature on specimen temperature, and
effects of temperature on mononuclear cell yield, viability and
immunologic function. J Transl Med 9: 26.

4. Catton M, Druce J, Papadakis G, Tran T, Birch C, 2011. Reality
check of laboratory service effectiveness during pandemic
(H1N1) 2009, Victoria, Australia. Emerg Infect Dis 17: 963–968.

5. Barin F, Meyer L, Lancar W, Deveau C, Gharib M, Laporte A,
Descenclos JC, Costagliola D, 2005. Development and validation of
an immunosay for identification of recent human immuno-
deficiency virus type 1 infections and its use on dried serum
spots. J Clin Microbiol 43: 4441–4447.

6. Monceau M, Montavon C, Laurent C, Segondy M, Montes B,
Delaporte E, Boililot F, Peeters M, 2009. Evaluation of different
RNA extraction methods and storage conditions of dried
plasma or blood spots for human immunodeficiency virus type
1 RNA quantification and PCR amplification for drug
resistance testing. J Clin Microbiol 47: 1107–1118.

7. Abe K, Konoui N, 1998. Hepatitis C virus RNA in dried serum
spotted on filter paper is stable at room temperature. J Clin
Microbiol 36: 3070–3072.

8. Solmone M, Girardi E, Costa F, Pacilio L, Ippolito G, Capobianchi
MR, 2002. Simple and reliable method for detection and
genotyping of hepatitis C virus RNA in dried blood spots
stored at room temperature. J Clin Microbiol 40: 3512–3514.

9. Fukunaga T, Rojanasuphot S, Pusiphornkul S, Wungkorbkiat S,
Thammanichanon A, 1974. Serum epidemiology of arbo-
virus infections in the north-east and south of Thailand.
Biken J 17: 169–182.

10. Top FT Jr., Gunakasem P, Chantrasri C, Supavadee J, 1975.
Serologic diagnosis of dengue haemorrhagic fever using filter
paper discs and one dengue antigen. Southeast Asian J Trop
Med Public Health 6: 18–24.

11. Prado I, Rosario D, Bernardo L, Alvarez M, Rodriguez R,
Vazquez S, Guzman MG, 2005. PCR detection of dengue
virus using dried whole blood spotted on filter paper. J Virol
Methods 125: 75–81.

12. Matheus S, Meynard JB, Lacoste V, Morvan J, Deparis X, 2007.
Use of capillary blood samples as a new approach for diagnosis
of dengue virus infection. J Clin Microbiol 45: 887–890.

13. Balmaseda A, Saborio S, Tellez Y, Mercado JC, Perez L,
Hammond SN, Rocha C, Kuan G, Harris E, 2008. Evaluation of
immunological markers in serum, filter-paper blood spots,
and saliva for dengue diagnosis and epidemiological studies.
J Clin Virol 40: 287–291.

14. Anders KL, Nguyen NM, Quyen NT, Ngoc TV, Tram TV, Gan
TT, Tung NT, Dung NT, Chau NV, Wills B, Simmons CP,
2012. An evaluation of dried blood spots and oral swabs as
alternative specimens for the diagnosis of dengue and screen-
ing for past dengue virus exposure. Am J Trop Med Hyg
87: 165–170.

15. Wan E, Akana M, Pons J, Chen J, Musone S, Kwok PY, Liao W,
2010. Green technologies for room temperature nucleic acid
storage. Curr Issues Mol Biol 12: 135–142.

16. Balmaseda A, Saborio S, Tellez Y, Mercado JC, Perez L,
Hammond SN, Rocha C, Kuan G, Harris E, 2008. Evaluation of
immunological markers in serum, filter-paper blood spots,
and saliva for dengue diagnosis and epidemiological studies.
J Clin Virol 40: 287–291.

17. Anders KL, Nguyen NM, Quyen NT, Ngoc TV, Tram TV, Gan
TT, Tung NT, Dung NT, Chau NV, Wills B, Simmons CP,
2012. An evaluation of dried blood spots and oral swabs as
alternative specimens for the diagnosis of dengue and screen-
ing for past dengue virus exposure. Am J Trop Med Hyg
87: 165–170.
16. Mei JV, Alexander JR, Adam BW, Hannon WH, 2001. Use of filter paper for the collection and analysis of human whole blood specimens. *J Nutr 131*: 1631S–1636S.

17. Brandao CP, Marques BL, Marques VA, Villela-Nogueira CA, Do OK, de Paula MT, Lewis-Ximenez LL, Lampe E, Sa Ferreira JA, Villar LM, 2013. Simultaneous detection of hepatitis C virus antigen and antibodies in dried blood spots. *J Clin Virol 57*: 98–102.

18. Villar LM, de Oliveira JC, Cruz HM, Yoshida CF, Lampe E, Lewis-Ximenez LL, 2011. Assessment of dried blood spot samples as a simple method for detection of hepatitis B virus markers. *J Med Virol 83*: 1522–1529.

19. Demirev PA, 2013. Dried blood spots: analysis and applications. *Anal Chem 85*: 779–789.

20. Howlett SE, Castillo HS, Gioeni LJ, Robertson JM, Donfack J, 2014. Evaluation of DNAstable for DNA storage at ambient temperature. *Forensic Sci Int Genet 8*: 170–178.

21. Ivanova NV, Kuzmina ML, 2013. Protocols for dry DNA storage and shipment at room temperature. *Mol Ecol Resour 13*: 890–898.

22. Zanoni M, Giron LB, Vilhena C, Sucupira MC, Lloyd RM Jr., Diaz RS, 2012. Comparative effectiveness of dried-plasma hepatitis B virus viral load (VL) testing in three different VL commercial platforms using ViveST for sample collection. *J Clin Microbiol 50*: 145–147.

23. Zanoni M, Cortes R, Diaz RS, Sucupira MC, Ferreira D, Inocencio LA, Vilhena C, Loveady C, Lloyd RM Jr, Holodniy M, 2010. Comparative effectiveness of dried plasma HIV-1 viral load testing in Brazil using ViveST for sample collection. *J Clin Virol 49*: 245–248.

24. Lloyd RM Jr, Burns DA, Huong JT, Mathis RL, Winters MA, Tanner M, De La Rosa A, Yen-Lieberman B, Armstrong W, Taee A, McClerndon DR, Wetshtein JL, Friedrich BM, Ferguson MR, O’Brien W, Fecorino PM, Holodniy M, 2009. Dried-plasma transport using a novel matrix and collection system for human immunodeficiency virus and hepatitis C virus virologic testing. *J Clin Microbiol 47*: 1491–1496.

25. Forshey BM, Guevara C, Laguna-Torres VA, Cespedes M, Vargas J, Gianella A, Vallejo E, Madrid C, Aguayo N, Gotuzzo E, Suarez V, Morales AM, Beingoela L, Reyes N, Perez J, Negrete M, Rocha C, Morrison AC, Russell KL, Blair PJ, Olson JG, Kochel TJ, Group NFSW, 2010. Arboviral etiologies of acute febrile illnesses in western South America, 2000–2007. *PLoS Negl Trop Dis 4*: e787.

26. Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV, 1992. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. *J Clin Microbiol 30*: 545–551.

27. Johnson BW, Russell BJ, Lanciotti RS, 2005. Serotype-specific detection of dengue viruses in a fourplex real-time reverse transcriptase PCR assay. *J Clin Microbiol 43*: 4977–4983.

28. McAvin JC, Escamilla EM, Blow JA, Turell MJ, Quintana M, Bowles DE, Swaby JA, Barnes WJ, Huff WB, Lohman KL, Atchley DH, Hickman JR, Niemeyer DM, 2005. Rapid identification of dengue virus by reverse transcription-polymerase chain reaction using field-deployable instrumentation. *Mil Med 170*: 1053–1059.

29. Bland JM, Altman DG, 1986. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet 1*: 307–310.

30. Gilliland T Jr, Dauner AL, Pal S, Mitra S, Kochel T, Wu S-J, 2013. Evaluation of Sample Integrity Using Commercially Available RNA-Stabilizing Blood Collection Tubes. Bethesda, MD: Uniformed Services University Research Day.

31. Snit PW, Elliott I, Peeling RW, Mabey D, Newton PN, 2014. An overview of the clinical use of filter paper in the diagnosis of tropical diseases. *Am J Trop Med Hyg 90*: 195–210.